JPS6250448B2 - - Google Patents
Info
- Publication number
- JPS6250448B2 JPS6250448B2 JP54134124A JP13412479A JPS6250448B2 JP S6250448 B2 JPS6250448 B2 JP S6250448B2 JP 54134124 A JP54134124 A JP 54134124A JP 13412479 A JP13412479 A JP 13412479A JP S6250448 B2 JPS6250448 B2 JP S6250448B2
- Authority
- JP
- Japan
- Prior art keywords
- strains
- acid
- cephalexin
- mic
- gram
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229940106164 cephalexin Drugs 0.000 claims description 23
- ZAIPMKNFIOOWCQ-UEKVPHQBSA-N cephalexin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=CC=C1 ZAIPMKNFIOOWCQ-UEKVPHQBSA-N 0.000 claims description 20
- MHWLWQUZZRMNGJ-UHFFFAOYSA-N nalidixic acid Chemical compound C1=C(C)N=C2N(CC)C=C(C(O)=O)C(=O)C2=C1 MHWLWQUZZRMNGJ-UHFFFAOYSA-N 0.000 claims description 18
- 229960000210 nalidixic acid Drugs 0.000 claims description 16
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 claims description 15
- 229960000321 oxolinic acid Drugs 0.000 claims description 15
- 239000003242 anti bacterial agent Substances 0.000 claims description 10
- 241000894006 Bacteria Species 0.000 claims description 9
- 229960003022 amoxicillin Drugs 0.000 claims description 6
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 5
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000000203 mixture Substances 0.000 description 40
- 230000001580 bacterial effect Effects 0.000 description 24
- 239000000243 solution Substances 0.000 description 14
- 241000894007 species Species 0.000 description 14
- 230000003115 biocidal effect Effects 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 229940079593 drug Drugs 0.000 description 11
- 239000003814 drug Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 230000002195 synergetic effect Effects 0.000 description 10
- DIGADQKVPFDJSI-SPYBWZPUSA-N cefalexin pivoxil Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(=O)OCOC(=O)C(C)(C)C)=CC=CC=C1 DIGADQKVPFDJSI-SPYBWZPUSA-N 0.000 description 8
- 229950006669 cefalexin pivoxil Drugs 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 229940088710 antibiotic agent Drugs 0.000 description 7
- 229960004841 cefadroxil Drugs 0.000 description 7
- NBFNMSULHIODTC-CYJZLJNKSA-N cefadroxil monohydrate Chemical compound O.C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CC=C(O)C=C1 NBFNMSULHIODTC-CYJZLJNKSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 244000052769 pathogen Species 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 4
- 241000191967 Staphylococcus aureus Species 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 229950010765 pivalate Drugs 0.000 description 4
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 4
- 241000588921 Enterobacteriaceae Species 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- -1 dioxymethylene group Chemical group 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 241000588624 Acinetobacter calcoaceticus Species 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 102000009338 Gastric Mucins Human genes 0.000 description 2
- 108010009066 Gastric Mucins Proteins 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 231100000111 LD50 Toxicity 0.000 description 2
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 244000000058 gram-negative pathogen Species 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 229960001732 pipemidic acid Drugs 0.000 description 2
- JOHZPMXAZQZXHR-UHFFFAOYSA-N pipemidic acid Chemical compound N1=C2N(CC)C=C(C(O)=O)C(=O)C2=CN=C1N1CCNCC1 JOHZPMXAZQZXHR-UHFFFAOYSA-N 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000002211 ultraviolet spectrum Methods 0.000 description 2
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241000194107 Bacillus megaterium Species 0.000 description 1
- 241001103259 Baltimora Species 0.000 description 1
- 241000510930 Brachyspira pilosicoli Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 241000873310 Citrobacter sp. Species 0.000 description 1
- 241000147019 Enterobacter sp. Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 201000008225 Klebsiella pneumonia Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 208000037581 Persistent Infection Diseases 0.000 description 1
- 206010035717 Pneumonia klebsiella Diseases 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 241000607715 Serratia marcescens Species 0.000 description 1
- 241000607714 Serratia sp. Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241001221452 Staphylococcus faecalis Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 150000004718 beta keto acids Chemical class 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 125000005331 diazinyl group Chemical group N1=NC(=CC=C1)* 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 244000000059 gram-positive pathogen Species 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000005497 microtitration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT28934/78A IT1119708B (it) | 1978-10-20 | 1978-10-20 | Impiego di beta-chetoacidi eterociclici azotati come inibitori del trasferimento di fattori genetici di resistenza |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS5573612A JPS5573612A (en) | 1980-06-03 |
| JPS6250448B2 true JPS6250448B2 (fi) | 1987-10-24 |
Family
ID=11224798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP13412479A Granted JPS5573612A (en) | 1978-10-20 | 1979-10-17 | Antibacterial composition |
Country Status (3)
| Country | Link |
|---|---|
| JP (1) | JPS5573612A (fi) |
| BE (1) | BE879489A (fi) |
| IT (1) | IT1119708B (fi) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0384410A1 (en) | 1989-02-21 | 1990-08-29 | Banyu Pharmaceutical Co., Ltd. | Antimicrobial composition |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4982670A (fi) * | 1972-12-18 | 1974-08-08 | ||
| JPS5046673A (fi) * | 1972-11-22 | 1975-04-25 | ||
| JPS50108276A (fi) * | 1974-02-07 | 1975-08-26 |
-
1978
- 1978-10-20 IT IT28934/78A patent/IT1119708B/it active
-
1979
- 1979-10-17 JP JP13412479A patent/JPS5573612A/ja active Granted
- 1979-10-18 BE BE0/197705A patent/BE879489A/fr not_active IP Right Cessation
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5046673A (fi) * | 1972-11-22 | 1975-04-25 | ||
| JPS4982670A (fi) * | 1972-12-18 | 1974-08-08 | ||
| JPS50108276A (fi) * | 1974-02-07 | 1975-08-26 |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0384410A1 (en) | 1989-02-21 | 1990-08-29 | Banyu Pharmaceutical Co., Ltd. | Antimicrobial composition |
Also Published As
| Publication number | Publication date |
|---|---|
| IT1119708B (it) | 1986-03-10 |
| BE879489A (fr) | 1980-02-15 |
| IT7828934A0 (it) | 1978-10-20 |
| JPS5573612A (en) | 1980-06-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2893035B2 (ja) | 増強された抗菌剤組成物 | |
| MX2007010129A (es) | Derivados de beta-ciclodextrina como agentes antibacteriales. | |
| CN110123801B (zh) | 一种多臂aie分子在制备抗菌药物中的用途和抗菌药物 | |
| KR20150089086A (ko) | 박테리아 감염을 치료하기 위한 조성물 및 방법 | |
| Stutman et al. | In vitro antimicrobial activity of aztreonam alone and in combination against bacterial isolates from pediatric patients | |
| Klastersky et al. | Anaerobic infection in cancer patients: comparative evaluation of clindamycin and cefoxitin | |
| CN116617361A (zh) | 百里香酚在制备mcr-1酶抑制剂中的应用 | |
| Panwalker et al. | Efficacy of cinoxacin in urinary tract infections | |
| US4386070A (en) | Pharmaceutical compositions endowed with an antibacterial activity and their use in the treatment of infections due to gram-positive and gram-negative pathogens | |
| EP2317998B1 (en) | Fulvic acid and antibiotic combination | |
| JP4970931B2 (ja) | 抗菌作用を有し、ジアミンをベースとするグアニジン誘導体 | |
| JPH0820510A (ja) | 抗菌活性のある香辛料、およびこれを原料とする抗菌剤 | |
| KR102620652B1 (ko) | 미생물 콜로니화의 조절을 위한 치환된 톨란 | |
| US20060073156A1 (en) | Fosfomycin and n-acetylcysteine for the treatment of biofilms caused by escheric ia coli and other pathogens of the urinary tract | |
| JPS6250448B2 (fi) | ||
| Chin et al. | Synergy of Imipenem–A Novel Carbapenem, and Rifampin and Ciprofloxacin against Pseudomonasaeruginosa, Serratiamarcescens and Enterobacter Species | |
| US20180325863A1 (en) | Antimicrobial compositions for clostridium difficile | |
| Kline et al. | Comparative in-vitro activity of LY146032 and eight other antibiotics against gram-positive bacteria isolated from children | |
| CN112438989B (zh) | 一种非抗生素类抗菌组合物及其应用 | |
| RU2792679C1 (ru) | Бактерицидная фармацевтическая композиция для парентерального применения в форме лиофилизата с эндолизином | |
| AU2017235711B2 (en) | Enhanced tulathromycin | |
| EP0765161A2 (en) | Synergistic antibiotic compositions containing a perphyrin and an antibiotic | |
| HU199288B (en) | Process for producing synergetic pharmaceutical composition of antibacterial activity | |
| KR101047591B1 (ko) | 동물용 복합항생제 조성물 | |
| BR102015028254A2 (pt) | peptídeo sintético e seu uso como antimicrobiano |